Business

Cipla retains top slot in domestic pharma market

February 8th, 2010|

Drug company Cipla maintained its top position in the domestic market for the 12 months ended December, 2009, with a market share of 5.38 per cent — up 18 per cent over the year and ahead of Ranbaxy Laboratories and GlaxoSmithKline (GSK).

No place like home, finds Indian pharma

February 7th, 2010|

In a recent reversal, operations abroad are hampering profit.

Pharma deals in India: 2009 precursor to what 2010 holds

December 30th, 2009|

For the pharmaceutical sector, 2009 was a year when Indian manufacturing capabilities took centre stage. For the first time, global pharmaceutical giants like Pfizer and GlaxoSmithKline (GSK) came shopping for Indian manufacturers. Pharmaquest.biz recaps some of biggest inbound pharma deals this year.

FMCG, pharma fledglings in for better days

December 20th, 2009|

The market has recently seen the re-rating of small companies in the FMCG and pharma sectors. FMCG players Dabur India and Emami witnessed the stocks of their recently-acquired companies, Fem Care Pharma and Zandu Pharma getting re-rated. Similarly, pharma companies, Cadila Care and Elder Pharma, have seen a lot of price action in the stocks of Zydus Wellness and Elder Health Care, respectively which were hived-off into independent companies respectively.

Avon to gain from nod to Ranbaxy’s drug

December 6th, 2009|

Ranbaxy Laboratories exclusive launch of generic anti-herpes Valtrex (valacyclovir hydrochloride) tablets in the US will help a listed Indian drug company, Hyderabad-based Avon Organics.

BIG PHARMA AND BIOTECH

November 9th, 2009|

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts.

A 360 Degree Perspective for CEOs to drive Growth, Innovation and Leadership,

October 25th, 2009|

Companies seem to be hesitating in moving ahead as they wait for further improvements in the global economy. However, Frost & Sullivan believes that the best CEOs are already planning how their businesses will take advantage of the growth opportunities presented by the rebound.

Drug MNCs look at India as a market

October 6th, 2009|

The list of drug majors scouting for a suitable buy in India is long. But this time, the attraction is: India as a market, and not merely as an inexpensive destination to source and produce products, say consultants and lawyers observing the increased merger and acquisition (M&A) activity seen in the pharmaceutical space.

Pfizer plans major push into generics

September 10th, 2009|

Pfizer Ltd, the Indian subsidiary of the world’s largest drug maker Pfizer Inc., is making an aggressive play in the Indian generics or off-patent drugs market.

Frost & Sullivans Food & Beverage Focus 2009

July 23rd, 2009|

Growing awareness and increased investments lead to growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements sector, reveals Frost & Sullivan

Indian pharma firms swallow bitter pill in US, Europe

July 15th, 2009|

Last week, Lupin, Matrix Laboratories and Unichem Laboratories’ UK subsidiary Niche Generics figured in the list of companies under investigation by the European Commission for “knowingly delaying” the generic launch of a cardiovascular drug, Perindopril, by teaming with the innovator of the drug, Laboratories Servier. The European Commission said it would probe anti-trust violations against these manufacturers.

US study wants India to allow frivolous patenting

June 28th, 2009|

Multinational drug makers seem hell bent upon forcing the government to alter the patent regulations in their favour.

Pharma welcomes UK taxation pledge

April 22nd, 2009|

The UK government budget delivered in the gloom of the recession has provided good news for the industry, according to its leaders.

Present Scenario of The Biotech Industry

April 16th, 2009|

Last year, the Biotech industry as a whole achieved much better performance than the market. Both the NASDAQ Biotech Index and AMEX Biotech Index outperformed all three major market indices (Dow Jones Industrial Average, NASDAQ Composite and S&P 500) in a large margin. The major indices declined as much as 40%. While NASDAQ Biotech Index declined only 12.6%, and AMEX Biotech Index was down 17.7%.

Healthcare M & A activity could be impacted by further FCPA enforcement

April 10th, 2009|

Merger and acquisition activity within the pharmaceutical and medical device industries will likely increasingly be impacted by an uptick in the enforcement of the Foreign Corrupt Practices Act (FCPA), attorneys told Pharmaquest.biz

Radhakrishna Foodland to pop pharma pill for growth

April 5th, 2009|

Food services logistics company Radhakrishna Foodland is training its guns on a new business segment. The company, which runs the supply chain for clients such as McDonald’s, is wooing medicine manufacturers to transport life savings drugs under controlled temperature conditions across the country.

Foreign loans did not work for Wockhardt

April 4th, 2009|

Pharma major, Wockhardt, has been in the news for a while. This was after a flurry of events. Its chairman Habil Khorakiwala resigned elevating his son, Murtuza Khorakiwala to the post of Managing Director.

ICRI, Cranfield Univ, UK open admissions for PG course in clinical research

March 31st, 2009|

Institute of Clinical Research (India), ICRI in collaboration with Cranfield University, UK has called for applications for its two year full time course, MSc in Clinical Research. The course will start on August 3 at all its campuses in Bangalore, Mumbai, Delhi, Ahmedabad & Hyderabad.

Glaxo, Sanofi in talks for Shanta Biotch takeover

March 29th, 2009|

GlaxoSmithKline and Sanofi-Aventis are reported to be in separate talks to buy a majority stake in Indian biotechnology firm that pioneered indigenous recombinant vaccines, Shantha Biotech.

Mega deals to boost pharma offshoring to India

March 29th, 2009|

While the recent consolidation in pharma industry is an outcome of the challenges faced by the global pharma companies over the last few years, this spells good news for Indian pharmaceutical contract manufacturers such as Piramal Healthcare, Jubilant Organosys, Divis' Labs and Dishman Pharma.